Mapracorat

Mapracorat
Clinical data
Routes of
administration		Topical (ointment, eye drops)
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.217.969 Edit this at Wikidata
Chemical and physical data
FormulaC25H26F4N2O2
Molar mass462.489 g·mol−1
3D model (JSmol)
  • c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C
  • InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1 ☒N
  • Key:VJGFOYBQOIPQFY-XMMPIXPASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Mapracorat (INN, code names BOL-303242-X, ZK-245186[1]) is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis,[2] inflammation following cataract surgery,[3] and allergic conjunctivitis.[4] Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models.[1]

  1. ^ a b Cavet ME, Harrington KL, Ward KW, Zhang JZ (September 2010). "Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells". Molecular Vision. 16: 1791–800. PMC 2932489. PMID 20824100.
  2. ^ Clinical trial number NCT00944632 for "Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT00905450 for "Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT01289431 for "Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis" at ClinicalTrials.gov